News coverage about MISONIX (NASDAQ:MSON) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MISONIX earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.9756454951063 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Shares of MISONIX (NASDAQ MSON) opened at $10.45 on Tuesday. MISONIX has a fifty-two week low of $7.05 and a fifty-two week high of $12.00.

WARNING: “MISONIX (MSON) Given Daily Coverage Optimism Score of 0.16” was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/misonix-mson-given-daily-coverage-optimism-score-of-0-16/1701871.html.

MISONIX Company Profile

Misonix, Inc designs, manufactures, develops and markets minimally invasive therapeutic ultrasonic medical devices. The Company’s products include BoneScalpel surgical system (BoneScalpel), SonaStar Surgical Aspirator (SonaStar), and SonicOne Wound Cleansing and Debridement System (SonicOne). These devices primarily serve the neurosurgery, orthopedic surgery, plastic surgery, wounds, burn and maxillo-facial clinical specialties.

Insider Buying and Selling by Quarter for MISONIX (NASDAQ:MSON)

Receive News & Ratings for MISONIX Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MISONIX Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.